Sfriso P, Bindoli S, Doria A, Feist E, Galozzi P (2020) Canakinumab for the treatment of adult-onset Still’s disease. Expert Rev Clin Immunol 16(2):129–138

Article  PubMed  Google Scholar 

Efthimiou P, Kontzias A, Hur P, Rodha K, Ramakrishna GS, Nakasato P (2021) Adult-onset Still’s disease in focus: Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum 51(4):858–874

Article  PubMed  Google Scholar 

Gerfaud-Valentin M, Maucort-Boulch D, Hot A, Iwaz J, Ninet J, Durieu I et al (2014) Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients. Medicine (Baltimore) 93(2):91–99

Article  PubMed  Google Scholar 

Ruscitti P, McGonagle D, Garcia VC, Rabijns H, Toennessen K, Chappell M et al (2024) Systematic review and meta-analysis of pharmacological interventions in adult-onset Still’s disease highlights the beneficial role of biologic DMARDs. J Rheumatol. https://doi.org/10.3899/jrheum.2023-0995

Article  PubMed  Google Scholar 

Leavis HL, van Daele PLA, Mulders-Manders C, Michels R, Rutgers A, Legger E et al (2023) Management of adult-onset Still’s disease: evidence- and consensus-based recommendations by experts. Rheumatology. https://doi.org/10.1093/rheumatology/kead461

Article  PubMed Central  Google Scholar 

Parlar K, Ates MB, Egeli BH, Ugurlu S (2023) The clinical role of anakinra in the armamentarium against familial Mediterranean fever. Expert Rev Clin Immunol. https://doi.org/10.1080/1744666X.2023.2299230

Article  PubMed  Google Scholar 

Colafrancesco S, Priori R, Valesini G, Argolini L, Baldissera E, Bartoloni E et al (2017) Response to interleukin-1 inhibitors in 140 italian patients with adult-onset still’s disease: a multicentre retrospective observational study. Front Pharmacol 8:369

Article  PubMed  PubMed Central  Google Scholar 

Kalliolias GD, Georgiou PE, Antonopoulos IA, Andonopoulos AP, Liossis SN (2007) Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial. Ann Rheum Dis 66(6):842–843

Article  PubMed  PubMed Central  Google Scholar 

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344–349

Article  Google Scholar 

Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19(3):424–430

PubMed  Google Scholar 

Nordström D, Knight A, Luukkainen R, van Vollenhoven R, Rantalaiho V, Kajalainen A et al (2012) Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still’s disease. An open, randomized, multicenter study. J Rheumatol. 39(10):2008–2011

Article  PubMed  Google Scholar 

Laskari K, Tzioufas AG, Moutsopoulos HM (2011) Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still’s disease: a case-series study. Arthritis Res Ther 13(3):R91

Article  PubMed  PubMed Central  Google Scholar 

Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G, Cattalini M et al (2016) A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol 7:380

Article  PubMed  PubMed Central  Google Scholar 

Sfriso P, Priori R, Valesini G, Rossi S, Montecucco CM, D’Ascanio A et al (2016) Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients. Clin Rheumatol 35(7):1683–1689

Article  PubMed  Google Scholar 

Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L et al (2015) Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis 10:19

Article  PubMed  PubMed Central  Google Scholar 

Cavalli G, Franchini S, Aiello P, Guglielmi B, Berti A, Campochiaro C et al (2015) Efficacy and safety of biological agents in adult-onset Still’s disease. Scand J Rheumatol 44(4):309–314

Article  PubMed  Google Scholar 

Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A et al (2019) Adult-onset still’s disease biological treatment strategy may depend on the phenotypic dichotomy. Arthritis Res Ther 21(1):53

Article  PubMed  PubMed Central  Google Scholar 

Kilic B, Ozturk A, Karup S, Hacioglu E, Ugurlu S (2024) Efficacy and safety of biologic drugs in Still’s disease: a systematic review and network meta-analysis of randomized controlled trials. Rheumatology. https://doi.org/10.1093/rheumatology/keae295

Article  PubMed  PubMed Central  Google Scholar 

Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J (2005) Refractory adult onset Still's disease successfully treated with anakinra. Ann Rheum Dis 64(4):647–648.

Kedor C, Listing J, Zernicke J, Weiß A, Behrens F, Blank N et al (2020) Canakinumab for treatment of adult-onset still’s disease to achieve reduction of arthritic manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 79(8):1090–1097

Article  PubMed  Google Scholar 

Kaneko Y, Kameda H, Ikeda K, Ishii T, Murakami K, Takamatsu H et al (2018) Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 77(12):1720–1729

Article  PubMed  Google Scholar 

Suzuki S, Kataoka Y, Otani T, Taniguchi Y, Ikeda K, Tamura N et al (2024) Optimal time of starting tocilizumab in acute phase of adult-onset Still’s disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature. Clin Rheumatol 43(3):1245–1251

Article  PubMed  PubMed Central  Google Scholar 

Vitale A, Cavalli G, Ruscitti P, Sota J, Colafrancesco S, Priori R et al (2020) Comparison of early vs. delayed anakinra treatment in patients with adult onset still’s disease and effect on clinical and laboratory Outcomes. Front Med (Lausanne). 7:42

Article  PubMed  PubMed Central  Google Scholar 

Ortiz-Sanjuán F, Blanco R, Riancho-Zarrabeitia L, Castañeda S, Olivé A, Riveros A et al (2015) Efficacy of anakinra in refractory adult-onset still’s disease: multicenter study of 41 patients and literature review. Medicine (Baltimore) 94(39):e1554

Article  PubMed  Google Scholar 

Kilic B, Guler Y, Azman FN, Bostancı E, Ugurlu S (2023) Efficacy and safety of anti-ınterleukin-1 treatment in familial Mediterranean fever patients: a systematic review and meta-analysis. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/kead514

Article  Google Scholar 

Tank ND, Karelia BN, Vegada BN (2017) Biological response modifiers in rheumatoid arthritis: systematic review and meta-analysis of safety. J Pharmacol Pharmacother 8(3):92–105

PubMed  PubMed Central  Google Scholar